Sign in Create account

Aarti Pharmalabs Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AARTIPHARM BSE: 543748
₹953.75
▼ -19.05 (-1.96%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
61/100
Moderate
Valuation
19/100
Expensive
Momentum
88/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Expensive, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹8,649 Cr
PE (TTM)
41.5
Industry median 36.1 (152 companies)
Price to Book
4.1
PEG (TTM)
-2.0
Institutions holding %
15.39%
FII + DII, latest filed period
Piotroski Score
3
Relative return vs Nifty50, qtr %
36.1
Relative return vs Sector, qtr %
35.9
Free Cash Flow
₹-147 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
39.29%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-17.82%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
11.62%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-40.37%
as of Dec. 31, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
42.44%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.49
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.32
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
6.27
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
10.31%
as of Dec. 31, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
20.41%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
16.97%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
5.36%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
11.30%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
8.78%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 3)
  • Yes Debt to equity is below 0.5 (0.32)
  • No Return on equity is 15% or more (8.8%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

1 of 4 met
  • No FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • No Promoter pledge is 5% of their holding or less and not rising (11.1% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

3 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.0%
Low 943.0000 · High 1002.4000
1W return
1.5%
Low 906.2000 · High 1002.4000
1M return
12.8%
Low 765.0000 · High 1002.4000
52W return
15.0%
Low 585.0000 · High 1002.4000
Lifetime High ₹972.8000 (Sept. 29, 2026)
Lifetime Low ₹247.1500 (Feb. 2, 2023)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
939.5
10D
913.8
20D
883.4
50D
828.6
100D
783.3
200D
734.0

Delivery and volume

Day avg. delivery
41.5%
Week avg. delivery
38.9%
Month avg. delivery
42.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

966.38
Pivot
First resistance989.77
Second resistance1025.78
Third resistance1049.17
First support930.37
Second support906.98
Third support870.97
Day RSI65.4
Day MFI87.5
Day MACD36.01
Day MACD signal26.40

Beta

1M2.59
3M1.18
1Y1.20
3Y1.12

Price change analysis

↑ 12.8%
Over 1 Month
LowHigh
765.001002.40
↑ 35.9%
Over 3 Months
LowHigh
650.801002.40
↑ 50.2%
Over 6 Months
LowHigh
604.151002.40
↑ 15.0%
Over 1 Year
LowHigh
585.001002.40
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 41.5 (own history: 19.6–31.7)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹535 Cr
Net profit (June 30, 2026)
₹71 Cr
Basic EPS (June 30, 2026)
₹7.8700

Ranks #48 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter42.86%
  • Mutual funds0.79%
  • FII/FPI8.17%
  • Other DII6.43%
  • Public41.75%

Largest holders

NameCategoryShares %Shares
Life Insurance Corporation Of IndiaPublic5.2700%4782452
Rashesh Chandrakant GogriPromoter4.2300%3834404
Jaya Chandrakant GogriPromoter3.5300%3204310
Anushakti Enterprise Private LimitedPromoter3.3000%2992950
LABDHI BUSINESS TRUST(Saswat Trusteeship Private Limited)Promoter3.1300%2841504

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings decreased from 43.08% to 42.86% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 8.39% to 8.17% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 0.80% to 0.79% in Jun 2026 qtr

1 mutual fund scheme also holds this stock.

All shareholding details →

Insider trading, SAST & pledges

All 53 insider trades, 4 SAST, 2 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
4 Mar 2026 Mirik Rajendra Gogri Promoter group Sell 0 ₹0
15 Dec 2025 Narendra J Salvi Key managerial personnel Sell 0 ₹0
5 Dec 2025 Hetal Gogri Gala Promoter group Buy 0 ₹0
4 Dec 2025 Hetal Gogri Gala Promoter group Buy 0 ₹0
26 Sep 2025 Manjula Mahendra Sangoi Immediate relative Sell 0 ₹0
22 Sep 2025 SAFECHEM ENTERPRISES PRIVATE LIMITED Promoter group Sell 0 ₹0
19 Sep 2025 SAFECHEM ENTERPRISES PRIVATE LIMITED Promoter Sell 0 ₹0
26 Aug 2025 ORCHID FAMILY TRUST (Relacion Trusteeship Services Private Limited) Promoter Sell 0 ₹0
1 Jul 2025 Nikhil Parimal Desai Promoter group Sell 0 ₹0
1 Jul 2025 ORCHID FAMILY TRUST (Relacion Trusteeship Services Private Limited) Promoter Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 39 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
21 Sep 2026 UNIFI CAPITAL PRIVATE LIMITED Bulk Buy 915,000 820.0000 NSE
21 Sep 2026 UNIFI CAPITAL PRIVATE LIMITED Bulk Buy 915,000 820.0000 NSE
18 Sep 2026 JASMINE FAMILY TRUST Bulk Sell 627,500 820.0200 NSE
18 Sep 2026 JASMINE FAMILY TRUST Bulk Sell 627,500 820.0200 NSE
18 Sep 2026 JASMINE FAMILY TRUST Bulk Sell 627,500 820.0200 NSE
11 Aug 2026 QE SECURITIES LLP Bulk Buy 576,747 899.5200 NSE
11 Aug 2026 QE SECURITIES LLP Bulk Sell 570,009 902.1800 NSE
11 Aug 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 640,653 903.7300 NSE
11 Aug 2026 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 640,416 903.3900 NSE
11 Aug 2026 MICROCURVES TRADING PRIVATE LIMITED Bulk Sell 717,028 904.3500 NSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹1.50 per share
Dividend yield 0.16%
Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 2.0000 — —
16 Feb 2026 Interim Dividend - Rs 1.50 Per Share 1.5000 16 Feb 2026
15 Sep 2025 Dividend - Rs 2.50 Per Share 2.5000 15 Sep 2025
14 Feb 2025 Interim Dividend - Rs 2.50 Per Share 2.5000 14 Feb 2025
31 Jul 2024 Dividend - Re 1 Per Share 1.0000 31 Jul 2024
16 Feb 2024 Interim Dividend - Rs 2 Per Share 2.0000 19 Feb 2024

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
7 Aug 2026 Financial Results Yes
25 May 2026 Financial Results/Dividend Yes
18 May 2026 Financial Results/Dividend Yes
9 Feb 2026 Financial Results/Dividend Yes
9 Nov 2025 Financial Results Yes

Corporate Announcements

All 246 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 Company Update Aarti Pharmalabs Ltd - 543748 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
30 Sep 2026 Company Update Aarti Pharmalabs Ltd - 543748 - Intimation Under Regulation 30 Of SEBI Listing Regulations
30 Sep 2026 General Updates Aarti Pharmalabs Limited has informed the Exchange about Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
30 Sep 2026 Updates Aarti Pharmalabs Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI Listing Regulations- Reconstitution of Committee of the Board of Directors'.
28 Sep 2026 Insider Trading / SAST Aarti Pharmalabs Ltd - 543748 - Closure of Trading Window
28 Sep 2026 Trading Window Aarti Pharmalabs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
23 Sep 2026 Updates Aarti Pharmalabs Limited has informed the Exchange regarding 'Updates on Change in Directorate'.
23 Sep 2026 Shareholders meeting Aarti Pharmalabs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 22, 2026. Further, the company has informed the Exchange regarding voting results.
22 Sep 2026 Updates Aarti Pharmalabs Limited has informed the Exchange regarding 'Presentation made to the shareholders at 7th AGM'.
22 Sep 2026 Shareholders meeting Aarti Pharmalabs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 22, 2026

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (42.4%)

Weaknesses

  • Low Return on Equity (8.8%)
  • Declining profit YoY (-40.4%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (41.5) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Aarti Pharmalabs Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.